Amylyx Pharmaceuticals is helping patients follow the clues to uncover the mystery of rare weight-loss surgery complication post-bariatric hypoglycemia (PBH) with the launch of a new patient education ...
Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. | Legend Biotech's Ying Huang, Ph.D., resigned after a six-year stint as CEO. Merck briefly posted—and then quickly ...
A Daiichi Sankyo quarterly report that should have celebrated strong commercial execution was instead derailed by an accounting error and manufacturing losses. | A Daiichi Sankyo quarterly report that ...
Reporting a new miss in one indication, Karyopharm Therapeutics is plowing ahead with plans to advance its XPO1 inhibitor Xpovio in another, despite investors blanching at that dataset back in March.
Since they were approved four months apart in 2019, AbbVie’s Skyrizi and Rinvoq have been joined at the hip, central to the Illinois drugmaker's hopes that the duo could replace aging immunology su | ...
Is biotech taking a trip to the world of psychedelic drugs? Why is Novo Nordisk going after Eli Lilly’s Zepbound ads? | This week on “The Top Line,” Fierce’s Zoey Becker, Will Maddox and Kevin ...
Investors anxiously waiting for Bristol Myers Squibb’s key Alzheimer’s disease psychosis readout for Cabenfy will have to ...
In hopes of challenging Incyte’s topical JAK inhibitor Opzelura, Pfizer is headed to regulators with results from a pair of ...
Regeneron’s cut from the Dupixent sales boom was $2.11 billion in the quarter, which topped analysts’ consensus by $358 ...
New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat
In her inaugural earnings call as the new CEO of Sanofi, Belén Garijo—until recently head honcho at Germany’s Merck KGaA—laid out her ambitions for the French pharma juggernaut, plainly addressing the ...
Amgen, LeBron James and world’s top-subscribed YouTuber MrBeast may sound like a Mad Lib of unrelated influences, but the ...
Alnylam Pharmaceuticals’ stock price plummeted as much as 29% Thursday morning after disappointing Amvuttra sales and a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results